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A Controversial New Hope
Exploring recent advancements in Alzheimer’s disease treatment
By Lauren Limbach
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The Aduhelm
Controversy

M

ost people would
probably acknowledge that they’ve
made a mistake at work from time
to time. This is what happened
to *Joe, a successful industrial
researcher, who one day noticed
that he had made a calculation
error while at work. But this wasn’t
an isolated incident, these types
of calculation errors kept happening with increasing frequency.
Eventually the repeated mistakes
forced him to step away from a
job in which he used to thrive. This
trend continued for several years,
causing him to bounce from job
to job, before he was eventually
fired and became unemployed.
But the changes that Joe experienced weren’t limited to mistakes
at work. Joe began having difficulty navigating places he had been
many times before, and eventually
he lost the ability to perform many
basic tasks such as maintaining
personal hygiene [1]. Based on
these symptoms, you may not be
surprised to learn that Joe was
eventually diagnosed with Alzheimer’s disease (AD). However what
may be surprising is Joe’s age: he
was diagnosed with AD at the age
of 37 [1].
Alzheimer’s disease (AD) is
a neurodegenerative disease characterized by drastic deteriorations
in a patient’s cognition, memory
and overall function — all of which
were observed in Joe’s case [2].
AD also imposes large financial
and emotional burdens on families
and caregivers, and often necessitates entry into a nursing home [3].
The vast majority of AD diagnoses
are made in elderly individuals,
while a smaller number of cases
like Joe’s are diagnosed early in
life [2]. Over 6 million Americans
are currently living with AD, yet AD
is not often a topic of daily conversation despite the widespread and

devastating effects imposed by the
disease [3].
However, in the summer of
2021, AD was frequently featured
in media headlines because of
the US Food and Drug Association’s (FDA) decision to approve
Aduhelm: an innovative new drug
designed to treat AD. Despite being the first AD drug approved in
twenty years, the media coverage
of Aduhelm’s approval was largely negative. Confusion over the
drug’s efficacy and the basis for
the FDA’s decision overshadowed
what could have been a victory
for everyone involved in the fight
against AD. Shortly following
the approval of Aduhelm, stories
detailing the departure of several
members of the FDA’s advisory
board began circulating in the
news. These individuals cited their
disagreement with Aduhelm’s
approval as the motivating factor
behind their departure from the
FDA, stirring public intrigue as to
whether or not the FDA’s decision
was a sound one [4]. After the
board members’ departure, the
acting FDA commissioner initiated
an external investigation into the
proceedings that led to Aduhelm’s
approval [5]. The acting commissioner stated that the primary
motivation for launching the investigation was to reestablish public
confidence in the FDA approval
process [5]. However, launching
the external investigation fueled
the fire of public speculation that
something was amiss in regards
to Aduhelm’s approval. What
followed over the next several
weeks was an onslaught of attention-grabbing headlines such as:

“New Alzheimer’s drug could
cost the government as much as
it spends on NASA”
- New York Times
Overall, the media coverage of Aduhelm painted the drug
as an uninspiring advancement
in AD treatment, and a potential misstep by the FDA. Many
articles questioned the efficacy
of Aduhelm [6], [7], and others
highlighted the high price tag
associated with the drug [8], [9].
Some characterized the rollout of
the drug as unsuccessful and cited
numerous reputable hospitals and
insurance companies who were
choosing not to prescribe or cover
Aduhelm [10], [11].
Additionally, in October of
2021 the biotechnology company Eli Lilly filed for FDA approval
of their new Alzheimer’s drug,
Donanemab, which is mechanistically quite similar to the controversial Aduhelm drug [12], [13], [14].
This raises the question of whether
or not the FDA will grant approval
to an AD drug similar to Aduhelm
after the backlash that resulted
from their original approval. The
Aduhelm controversy and recent
developments with Donanemab
highlight the importance of investigating the biological basis of AD,
as well as how these treatments fit
into our current understanding of
AD.

“How Aduhelm, an unproven
Alzheimer’s drug, got approved”
- New York Times
“FDA Approved Biogen Alzheimer’s Drug Despite Some Staff
Concerns”
- Wall Street Journal
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Are amyloid-β
proteins the
underlying cause of
AD?
For the last several decades, the most commonly accepted explanation for AD has been
the amyloid-β hypothesis: AD
symptoms arise due to aggregations of amyloid-β proteins in the
brain [15]. According to the biological definition of AD, the buildup of amyloid-β proteins is a necessary precursor for an individual
to be diagnosed with AD [16]. Amyloid-β proteins are derived from
the breakdown of the amyloid precursor protein (APP): a protein that
is found in neurons and that plays
an unknown role in their growth
and survival [17]. APP is normally
broken down by an enzyme called

the α-secretase (Figure 1), [17]. The
breakdown of APP by α-secretase
produces benign byproducts that
do not contribute to AD pathology [17]. However APP can also
be broken down by two different
enzymes, β-secretase and γ-secretase, which yield slightly different
products than those produced by
the normal pathway (Figure 1),
[2]. Among those products are
amyloid-β proteins [2]. The physical properties of these amyloid-β
proteins make it easy for them to
combine into clumps, referred to
as insoluble plaques or fibrils [17].
Amyloid-β plaques are arguably
the most prominent feature of
AD pathology, and are thought to
underlie the cognitive and behavioral abnormalities associated with
AD [2]. Research has suggested
that the balance between the two
pathways for breaking down APP is
different in AD patients compared
to non-AD patients, leading to

increased production of amyloid-β
in AD patients [2].
If there is so much evidence that amyloid-β is the underlying cause of AD, then why have
the collective efforts of researchers
around the globe not resulted
in an amyloid-β-clearing treatment capable of curing AD? And
why are there studies circulating
saying that the severity of amyloid-β plaque buildup isn’t even
predictive of the severity of AD
symptoms [2]? There are several
viable theories for why this is the
case. Some scientists think that the
initial presence of amyloid-β proteins, rather than the quantitative
buildup of amyloid-β over time,
triggers a chain of events that
leads to the clinical symptoms of
AD [2]. In this scenario the quantitative extent of amyloid-β buildup
would not predict symptom severity because the symptoms would
not result from amyloid-β aggrega-

Figure 1. Possible pathways for APP breakdown. Original image by Lauren Limbach. Created in BioRender.
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Figure 2. “Biogenesis of types 1 and 2 Aβ oligomers in the brain” by Karen Hsiao Ashe is available under CC
BY-NC 4.0. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984270/)
tion, but would instead result from
meree amyloid-β presence [2].
Should this theory be true, amyloid-β-clearing drugs would likely
prove ineffective in alleviating the
symptoms of AD once the initial
presence of amyloid-β triggered
the ensuing downstream effects
[2]. A second theory suggests that
only a subset of amyloid-β proteins
are AD-causing agents, and that
the clinical symptoms of AD are associated with the quantity of these
particular amyloid-β subtypes, as
opposed to amyloid-β aggregation
as a whole [2]. If this is the case,
amyloid-β-based treatments for
AD would only be effective if they
target the specific disease-causing
subtypes of amyloid-β [2].
In fact, recent developments in AD research support the
hypothesis that not all amyloid-β
buildup plays an equal role in AD

pathology. Most AD pharmaceutical trials target insoluble amyloid-β: clusters of amyloid-β oligomers that form a plaque or fiber
[18]. However another form of amyloid-β, soluble amyloid-β oligomers, may be wreaking the most
havoc in the brains of AD patients
[18], (Figure 2). Soluble amyloid-β
oligomers are smaller and more
mobile than amyloid-β plaques,
and appear to be more toxic than
insoluble amyloid-β oligomers [2].
If this is the case, the many unsuccessful attempts to treat AD by
dissolving amyloid-β plaques may
be due to the fact that the soluble amyloid-β oligomers, rather
than the insoluble plaques, are to
blame for AD symptoms [18].
So what do scientists think
are the effects of soluble oligomers and how do they lead to the
devastating clinical symptoms of

AD? They are perhaps implicated
in the ability to form memories.
Memory formation is a complex
process, and its loss is perhaps
the most commonly recognized
symptom of AD. Memory formation relies on a complex molecular
process called long-term potentiation in which the connections between certain neurons in the brain
are strengthened over time [19].
Soluble amyloid-β oligomers are
capable of altering the proteins
on the exterior of neurons, which
can prevent long-term potentiation from taking place (Figure
3), [19]. The hindrance of longterm potentiation in AD patients
by soluble amyloid-β oligomers
would provide a powerful explanation for the memory loss and
cognitive deficits experienced by
AD patients. Furthermore, overall
cognitive functioning is dependent
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Figure 3. Downstream effects of amyloid-β proteins. Original image by Lauren Limbach. Created in BioRender.
on timely and accurate communication between neurons. This
occurs via the release of small
biological containers called synaptic vesicles that contain messenger
molecules called neurotransmitters
[19]. Soluble amyloid-β oligomers have been demonstrated to
interact with many of the proteins
involved in synaptic vesicle generation and release, providing a
potential pathway through which
amyloid-β oligomers may interfere
with neuronal communication and
as a result, cognitive functioning
(Figure 3), [19].

Neuroinflammation
in AD
Recently there has been
an increased focus on the link
between amyloid-β aggregation
and neuroinflammation, as well as
what role this relationship plays in
AD pathology. Neuroinflammation
occurs when the brain’s immune
system is activated in response to
a threatening stimulus such as a
foreign pathogen [17]. Neuroinflammation is mediated by microglia: a group of cells within the
central nervous system (CNS) that
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are responsible for defending the
brain and spinal cord from exterior
threats [17]. Microglia are essential
for maintaining stability within the
CNS, and as such, microglial and
neural immune dysfunction have
been speculated to play a role in
AD [17].
Microglia are responsible
for clearing amyloid-β following
its secretion from neurons [17]. It
is important for amyloid-β to be
broken down soon after its release
because its molecular makeup
makes it easy for it to assemble
into oligomers and plaques [17].
The delicate balance of amyloid-β secretion and removal can
be upset and result in amyloid-β
accumulation if neurons increase
their production of amyloid-β to
the point where the microglia can’t
keep up [17].
When microglia detect a
threat in the environment, they
enter a distinct activated state and
release molecules called proinflammatory cytokines that promote
inflammation and other immune
responses [17]. Microglia contain
receptors capable of identifying
amyloid-β in their environment,
meaning that microglia become
chronically activated following

amyloid-β accumulation [17]. This
chronic activation causes microglia
to release copious amounts of the
proinflammatory cytokines TNF-α
and Il-1β, which have been found
in higher levels in the brains of
AD patients [17]. While microglial
activation and proinflammatory
cytokine release may be helpful
following exposure to an isolated
pathogen, the long-term continuation of these responses is damaging to the brain [17]. Elevated
TNF-α and Il-1β levels have been
associated with declining cognitive
abilities, suggesting a direct role
for neuroinflammation in a hallmark characteristic of AD clinical
pathology [17]. Neuroinflammation
may also increase the severity of
AD pathology in patients because
there is a positive feedback loop
between neuroinflammation and
amyloid-β production: neuroinflammation activates the enzymes
that generate amyloid-β, increasing its accumulation in the brain
over time [17]. However, the
precise role that neuroinflammation plays in AD pathology remains
unclear, making it a promising area
of future research — particularly as
the search continues for effective
treatments for AD.
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Current treatments
for AD
The Alzheimer’s Association website breaks down the
currently available pharmaceutical treatments for AD into two
broad categories: “Drugs that may
change disease progression” and
“Drugs that treat symptoms” [20].
Aduhelm is the only drug that is
acknowledged to potentially possess the ability to change disease
progression of AD. The other
drugs may be effective at addressing the symptoms of AD, but have
no effect on the eventual advancement of the disease. These symptom-oriented drugs fall into four
classes: cholinesterase inhibitors,
glutamate regulators, cholinesterase inhibitor + glutamate regulator
combinations and orexin receptor
antagonists [20]. The drugs in each
category mitigate AD symptoms
by targeting neurotransmitter
systems that are disrupted in the
brains of AD patients. Therefore,
these drugs attempt to remedy the
downstream effects of amyloid-β
aggregation, rather than directly
addressing amyloid-β aggregation
itself.

Cholinesterase inhibitors,
one class of symptom-oriented AD
drugs, prevent the breakdown of
the neurotransmitter acetylcholine
[21]. The acetylcholinergic system
is integral to memory formation,
and AD-associated memory loss
likely partially results from decreased acetylcholine production
due amyloid-β aggregation [22].
Furthermore, decreased acetylcholine activity may increase the
formation of amyloid-β plaques
[22]. Cholinesterase inhibitors
that increase acetylcholine activity therefore not only address the
shortage of acetylcholine that results from amyloid-β formation, but
may slow the pace of amyloid-β
accumulation by elevating acetylcholine activity. Clinical trials have
demonstrated that cholinesterase
inhibitors are capable of improving
the cognitive abilities and overall
functioning levels of AD patients,
albeit to a limited extent [22], [21].
In addition to the acetylcholine system, another neurotransmitter system associated
with AD pathology is the glutamate system. Amyloid-β affects
glutamate activity in an opposite
manner than it does acetylcholine. By blocking the reuptake of

glutamate molecules back into
neurons, amyloid-β aggregation
leads to an excess of glutamate
that continually activates neuronal
glutamate receptors (Figure 3)
[19]. Overactivation of glutamate
receptors can lead to changes
in gene expression that impact
cell functioning and survival [19].
Glutamate regulating drugs designed to treat AD block neuronal
glutamate receptors, thus preventing the buildup of glutamate from
overactivating glutamate receptors [23]. Similar to cholinesterase
inhibitors, glutamate regulators
are capable of improving cognitive
and global functioning levels to a
limited extent in AD patients [23].
Glutamate regulators are often
prescribed in addition to cholinesterase inhibitors [23]. Simultaneous
treatment with both classes of
drugs may improve outcomes by
addressing the separate effects
of amyloid-β aggregation on two
different neurotransmitter systems.
The other drug category listed on the Alzheimer’s
Association website consists of
orexin antagonists. Orexin is a
neurotransmitter responsible for
keeping individuals awake and
alert [24]. Its role in AD is support-

“Brain Inflammation from Alzheimer’s Disease” by NIH Image Gallery. 2017. Flickr.
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ed by the fact that patients with
moderate to severe AD exhibit
increased orexin levels compared
to patients with mild AD [24].
Furthermore, AD patients often
exhibit abnormal sleep/wake
cycles, including insomnia: the
primary AD symptom that orexin
antagonists are designed to treat
[24]. Orexin dysregulation and
amyloid-β aggregation also appear
to be connected. Blocking orexin
activity reduces amyloid-β levels,
suggesting that orexin influences
amyloid-β dynamics, although the
precise nature of this relationship
remains unknown [24].
The current treatment
options available to AD patients
attempt to address the symptoms
of AD through a variety of pharmaceutical methods targeting different neurotransmitter networks.
While these treatments may have
positive impacts on the patient’s
cognitive and functional abilities,
or delay the patient’s entry into a
nursing home, they do not address the underlying causes of AD,
and therefore do not represent a
cure. The only drug that currently
targets the underlying biology of
AD is Aduhelm. However, even the
Alzheimer’s Association website
states that Aduhelm “may change
disease progression,” indicating
that a lot of uncertainty remains
regarding its efficacy. So how
exactly does Aduhelm work? And
in what ways is it different from the
current treatments available to AD
patients?

Aduhelm and
Donanemab
Instead of addressing
the adverse effects of amyloid-β
aggregation, Aduhelm and
Donanemab target amyloid-β
aggregation itself. Both Aduhelm
and Donanemab belong to a
class of pharmaceuticals known as
monoclonal antibodies [12], [14].
Antibodies are generated natu-
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rally by our immune system and
are used to identify and destroy
potentially harmful pathogens
[25]. In recent decades, antibody
production has been harnessed
by the biotechnology industry to
produce therapeutic monoclonal
antibodies. Biotechnology companies can design and produce
antibodies that target biological
threats of interest. The antibodies
are then administered to patients
to prompt the immune system to
mount an attack against the pathogen of interest. In addition to their
use in AD treatments, monoclonal
antibodies can be used to treat a
host of other disorders from asthma to leukemia, and have recently
demonstrated potential for treating COVID-19 [25], [26]. Currently
therapeutic antibody treatments
are one of the largest areas of biomedical research and account for
50% of biomedical sales revenue
[27].
Aduhelm and Donanemab
both attempt to treat the underlying biological cause of AD by
using monoclonal antibodies to
target and breakdown amyloid-β
plaques in AD patients [12], [14].
The main difference between the
two drugs is that Aduhelm targets
the entire amyloid-β sequence in
humans, while Donanemab recognizes a specific region of the amyloid-β protein [12], [14]. Because
of their slightly different targets,

Aduhelm and Donanemab have
differing abilities to bind soluble
and insoluble amyloid-β. Aduhelm
is capable of binding soluble
amyloid-β oligomers and insoluble amyloid-β plaques, whereas
Donanemab’s more targeted sequence means that it only binds to
insoluble amyloid-β plaques [12],
[28].
A phase 1 clinical trial found some evidence that
Aduhelm reduces amyloid-β
aggregation and slows the clinical
progression of AD [12]. However,
it is important to note that assessing the clinical symptoms of AD
was not the primary focus of this
study, and therefore these findings
remain promising but inconclusive [12]. Following administration
of Aduhelm, greater numbers of
microglia were identified in close
proximity to amyloid-β plaques,
suggesting that Aduhelm may induce microglial phagocytic activity
to facilitate amyloid-β clearance
[12]. Similarly, a phase 2 clinical trial identified cognitive and
functional benefits to Donanemab
treatment in AD patients, as well
as increased amyloid-β clearance
[14]. These initial results suggest
an incredibly promising future for
amyloid-β monoclonal antibody
treatments — so why is there such
controversy surrounding the FDA
approval process?
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The Future of AD
Research and
Treatments
The FDA granted approval
of Aduhelm via the accelerated
approval pathway [29]. This pathway does not represent permanent approval, nor does it mean
that the FDA views Aduhelm as
a definitive cure for AD. What it
does mean is that the FDA believes it has strong evidence that
Aduhelm successfully targets an
underlying, physiological cause of
AD: in this case, amyloid-β plaques
[29]. Because there are no other
viable treatments targeting the
underlying cause of AD, the FDA
is allowing patients to start taking
Aduhelm based only on its success
in clearing amyloid-β [29]. What
remains to be seen is whether or
not its success in clearing amyloid-β translates into cognitive and
functional improvements in AD
patients. Biogen is currently con-

ducting experiments to determine
whether or not this is the case, and
if Aduhelm’s efficacy for treating
the clinical symptoms of AD remains unproven, the FDA may revoke its approval. The accelerated
approval pathway through which
Aduhelm was approved rests on
a basic assumption: ameliorating
the underlying source of a disease
will alleviate the associated clinical
symptoms as well. It is a relatively
valid assumption, although its accuracy likely varies based on how
many factors are involved in the
etiology of any given disease. AD
is an extremely complex disease
whose underpinnings remain incompletely understood after years
of research. While this article has
focused on the complexities associated with amyloid-β aggregation
and neuroinflammation, there are
other biological factors associated with AD including neurofibrillary tangles and loss of synaptic
connections, not to mention the
roles of genetics, environmental
conditions, comorbidities, gender,

nutrition, physical activity and so
much more [30].
So will the clearance of
amyloid-β plaques facilitated by
Aduhelm reduce the clinical symptoms of AD? The short answer
is maybe. Despite the extremely tangled web of contributing
factors, amyloid-β does seem to
play a large role in AD, and clearance of amyloid-β plaques may
prove effective at alleviating the
clinical symptoms of the disease.
However, as previously discussed,
amyloid-β plaques may be of secondary importance compared to
soluble amyloid-β oligomers when
it comes to AD onset and progression [18], [2]. It therefore remains
to be seen whether or not the
clearance of amyloid-β plaques will
prove sufficient for alleviating the
cognitive and functional symptoms
of AD. If so, treatments such as
Aduhelm and Donanemab would
represent a major step forward in
addressing one of the most pressing biomedical issues of our time.
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